Table 2 Characteristics of pediatric intensive care unit stay of patients with sickle cell disease
All patients (N = 579) | Patients with adverse outcome (N = 113) | Patients without adverse outcome (N = 466) | MD | p-value | |
|---|---|---|---|---|---|
Biological datas | |||||
Maximum CRP (mg/L) | 117 [54–189] (< 10–467) | 126 [68–173] (< 10–409) | 110 [50–193] (< 10–467) | 100 | NS |
Minimal hemoglobin (g/dl) | 8.0 [6.8-9.0] (2.3–12.9) | 7.2 [6.1–8.3] (3.3–12.3) | 8.2 [6.9–9.2] (2.3–12.9) | 23 | < 0.01 |
Maximum delta of hemoglobin during stay | 0 [0.0-1.2] (-0.7-6.7) | 0.1 [0.0-1.6] (0.0-3.9) | 0.0 [0.0-1.1] (-0.7-6.7) | 23 | < 0.01 |
Maximal hemoglobin S percentage during stay (%) | 58 [41–72] (7–94) | 59 [40–78] (7–93) | 57 [43–70] (12–94) | 263 | NS |
Maximal white blood cell count (x103/mm 3) | 17.1 [13.0-23.3] (1.4–52.7) | 21.0 [15.0-27.4] (2.8–52.7) | 16.4 [12.8–22.1] (1.4–47.5) | 19 | < 0.01 |
Hyponatremia < 135 mmol/l, n (%) | 155 (29%) | 39 (36%) | 119 (28%) | 39 | NS |
Acute renal failure, n (%) | 16 (3%) | 8 (7%) | 8 (2%) | 29 | † |
Treatments | |||||
Ventilatory support | |||||
NIV, n (%) | 291 (50%) | 89 (79%) | 202 (43%) | 0 | < 0.01 |
Duration (days) | 2 [2–3] (0–9) | 4 [4–5] (0–9) | 2 [2–3] (0–3) | 0 | <0.01 |
MV, n (%) | 47 (8%) | 47 (41%) | 0 (0%) | 0 | - |
Duration (days) | 3 [2–6] (0–27) | 3 [2–6] (0–27) | - | 0 | |
Nitric oxide, n (%) | 20 (4%) | 11 (10%) | 8 (2%) | 1 | † |
High-frequency ventilation, n (%) | 6 (1%) | 6 (5%) | 0 (0%) | 1 | - |
Hemodynamic support, n (%) | |||||
Fluid resuscitation | 13 (3%) | 12 (12%) | 1 (0%) | 0 | † |
Vasoactive drugs | 12 (2%) | 12 (11%) | 0 (0%) | 0 | - |
Anti-infective therapy | |||||
Intravenous antibiotics, n (%) | 490 (85%) | 111 (98%) | 379 (82%) | 1 | < 0.01 |
Duration (days) | 6 [3–8] (0–57) | 8.5 [5–11] (0–57) | 5.0 [3–7] (0–20) | 2 | < 0.01 |
Hematologic support | |||||
Transfusion prior to admission, n (%) | 211(38%) | 43 (39%) | 168 (38%) | 39 | NS |
Number | 1 [1–1] (1–3) | 1 [1–1] (1–3) | 1 [1–1] (1–3) | 3 | NS |
Transfusion in PICU, n (%) | 222 (38%) | 59 (52%) | 163 (35%) | 1 | < 0.01 |
Number | 1 [1–1] (1–6) | 1 [1–1] (1–6) | 1 [1–1] (1–3) | 17 | < 0.01 |
Transfusion exchange in PICU, n (%) | 155 (27%) | 45 (40%) | 110 (24%) | 2 | < 0.01 |
Number | 1 [1–1] (1–3) | 1 [1–1] (1–3) | 1 [1–1] (1–2) | 6 | < 0.01 |
No transfusion at any time | 129 (23%) | 16 (14%) | 113 (24%) | 9 | 0.01 |
Nutritional support, n (%) | |||||
Enteral nutrition | 69 (12%) | 31 (28%) | 38 (8%) | 9 | < 0.01 |
Parenteral nutrition | 6 (1%) | 4 (4%) | 2 (0%) | 22 | † |
Renal replacement therapy, n (%) | 3 (1%) | 3 (3%) | 0 (0%) | 0 | † |
Invasive device, n (%) | |||||
Central catheter | 45 (8%) | 28 (25%) | 17 (4%) | 1 | < 0.01 |
Arterial catheter | 68 (12%) | 30 (27%) | 38 (8%) | 1 | < 0.01 |
Evolution | |||||
Length of stay (days) | 3 [1–4] (0–57) | 5 [4–7] (1–57) | 2 [1–3] (0–16) | 0 | < 0.01 |
Death during PICU stay, n (%) | 7 (1%) | 7 (6%) | 0 (0%) | 0 | - |
Timing of death (days) | 2 [1–7] (1–14) | 2 [1–7] (1–14) | - | ||
Death during 6 months follow up, n (%) | 7 (1%) | 7 (6%) | 0 (0%) | 0 | - |